Valrubicin, Inhibitor

Valrubicin

Cat. Num. AAA5758492

• Purity: 98.00%
• Synonyms: Valrubicin; AD-32; inhibitor

• Purity/Purification: 98.00%
• Form/Format: Solid. Powder

• Solubility: DMSO: 125mg/mL (172.74mM); Water: Insoluble; (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: C34H32F3NO13
• SMILES: CCCCC(OCC([C@]1(O)CC2=C(C(O)=C3C(C4=C(C(C3=C2O)=O)C=CC=C4OC)=O)[C@@H](O[C@]5C[C@](NC(C(F)(F)F)=O)[C@](O)[C@](C)O5)C1)=O)=O
• CAS Number: 56124-62-0
• Cell Research: UMSCC5 cells exposed to Valrubicin (2uM for 3 h), a single dose of radiation (400 cGy), or the combined treatment,are cultured for a further 12, 24, or 48 hours. At these times, the cells are collected by trypsinization (0.25%), washed in PBS, and fixed at 5 x 10^6 cells/mL with 95% ethanol. Cells are incubated with ribonuclease (50 ug; 70-90 Kunitzunits/mg for 30 min), and the resulting pellet resuspended in and incubated with propidium iodide (0.05mg/mL for 10 min). The DNA content of the samples is determined by flow cytometry according to standard technique [2].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Structure

Related Product Information for Valrubicin, inhibitor

Valrubicin (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25uM) and has antitumor and anti-inflammatory activity.

Product Categories/Family for Valrubicin, inhibitor

Cytoskeletal Signaling; PKC

References

Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol. 1992 Feb 18;43(4):865-72.
Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol. 1992 Feb 18;43(4):865-72.
Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110(12):2026-32.
Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110(12):2026-32.
Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167(2):288-95.
Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167(2):288-95.